Literature DB >> 18418926

[Application of nootropic agents in complex treatment of patients with concussion of the brain].

A V Tkachev.   

Abstract

65 patients with a mild craniocereberal trauma have been observed. Medical examination included among general clinical methods the following methods: KT (MRT) of the brain, oculist examination including the observation of eye fundus. For objectification of a patient' complaints the authors used orientation and Galvestona's amnesia tests, feeling scale (psychological test), the table to determine the level of memory. Tests have been carried out on the first, tenth and thirty day of the treatment. Patients of the first group received in a complex treatment -pramistar, patients of the second group - piracetam. Patients of both groups noted considerable improvement during a complex treatment (disappearance of headache, dizziness and nausea) and at the same time patients receiving pramistar had better restoration of orientation and feeling. Pramistar was also more effective in patients with amnesia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18418926

Source DB:  PubMed          Journal:  Lik Sprava        ISSN: 1019-5297


  3 in total

1.  Piracetam Facilitates the Anti-Amnesic but not Anti-Diabetic Activity of Metformin in Experimentally Induced Type-2 Diabetic Encephalopathic Rats.

Authors:  Shruti Pandey; Debapriya Garabadu
Journal:  Cell Mol Neurobiol       Date:  2016-09-01       Impact factor: 5.046

Review 2.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

3.  Comparison between the effect of liothyronine and piracetam on personal information, orientation and mental control in patients under treatment with ECT.

Authors:  Mousavi Seyed Ghafur; Mohammad Saadat; Mohamad Reza Maraci; Reza S Bagherian; Mina Mazaheri
Journal:  Indian J Psychiatry       Date:  2012-04       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.